Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV-DDI Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

NCT06533280
View directory record Official record
Conditions
HIV Infections
Interventions
Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

NCT00000810
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
10
States / cities
Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Not applicable Interventional

A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection

NCT00002176
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Combination Drug Treatment of Pediatric HIV Infection

NCT00001818
View directory record Official record
Conditions
HIV Infection
Interventions
Hydroxyurea
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 3 Interventional

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

NCT00002224
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Jul 22, 2026, 2:04 PM EDT
Not listed Phase 3 Interventional

Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs

NCT00006397
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Stavudine, Didanosine
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
13
States / cities
Berkeley, California • Los Angeles, California • Fort Lauderdale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

NCT00001114
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon alfa-2b, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
12
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections

NCT00001035
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Interferon alfa-2b, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
3
States / cities
Los Angeles, California • Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients

NCT00001048
View directory record Official record
Conditions
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions
Filgrastim, Cytarabine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
9
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study of Etravirine and GSK1265744

NCT00920296
View directory record Official record
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
GSK1265744
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

NCT00000671
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
70
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

NCT00001122
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Interaction With HIV Antiretroviral Agents

NCT02556268
View directory record Official record
Conditions
HIV-DDI
Interventions
Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children

NCT00000851
View directory record Official record
Conditions
HIV Infections
Interventions
Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 10 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
32
States / cities
Torrance, California • Aurora, Colorado • Farmington, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Not applicable Interventional

A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

NCT00002411
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

NCT00014937
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir, lamivudine/zidovudine, efavirenz, lamivudine, stavudine, zidovudine, didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
32
States / cities
Los Angeles, California • Denver, Colorado • Farmington, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Not applicable Interventional

The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease

NCT00002001
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Comparison of ddI Versus Zidovudine in HIV-Infected Patients

NCT00000979
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
70
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

NCT04630002
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Darunavir/Ritonavir (DRV/RTV), Etravirine (ETR)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV

NCT00001049
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 3 Months
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

NCT00007202
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
4
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Not applicable Interventional

A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection

NCT00002177
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

NCT00001066
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 15 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
87
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults

NCT00002427
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Stavudine, Didanosine
Drug
Lead sponsor
Research Institute for Genetic and Human Therapy
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stamford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 2:04 PM EDT